MDxHealth SA Business Summary

MDxHealth SA is a commercial-stage precision diagnostics company that generates revenue primarily through the sale of proprietary molecular tests and laboratory services focused on urologic oncology and infectious diseases. The company’s business model centers on a fee-for-service reimbursement structure from private payers and Medicare, driven by a specialized direct sales force in the United States. Its primary business segments are categorized by the clinical pathway of prostate cancer—ranging from pre-biopsy risk assessment (SelectMDx) and post-biopsy tissue testing (ConfirmMDx) to genomic profiling for treatment selection (Genomic Prostate Score, or GPS)—alongside a molecular diagnostic segment for urinary tract infections (Resolve mdx). MDxHealth competes directly with Myrologic diagnostic providers such as Myriad Genetics, Veracyte, and OPKO Health. Within this landscape, MDxHealth distinguishes itself as a comprehensive urology-focused leader, offering a vertically integrated menu of molecular tests specifically tailored to the urologist’s clinical workflow, a more specialized focus than the broader oncology portfolios of its primary competitors. The leadership team is headed by CEO Michael K. McGarrity, who joined in 2019 with over 30 years of experience in the healthcare and diagnostics sectors, including executive roles at Nanosphere and Stryker. He is supported by CFO Ron Kalfus, who previously led financial operations at Rosetta Genomics and possesses extensive experience in molecular diagnostics capital markets. The company’s scientific foundation stems from the pioneering work of co-founders Dr. Wim van Criekinge and Dr. Herman Spolders, who leveraged licensed epigenetic technology from Johns Hopkins University to establish the firm’s core intellectual property. The Board of Directors is chaired by Koen Hoffman, CEO of Value Square, and includes industry veterans such as Donnie M. Hardison. Significant institutional support has been provided by investors like MVM Partners and Valiance Advisors, reinforcing the company’s position as a consolidated leader in the uro-oncology diagnostic space.